Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medincell's cost of goods sold for the
six
months ended in Mar. 2026 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Medincell's Gross Margin % for the
six
months ended in Mar. 2026 was 100%.
Cost of Goods Sold is also directly linked to Inventory Turnover.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:
Medincell's Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.
Medincell Cost of Goods Sold Related Terms
Medincell Cost of Goods Sold Historical Data
* Premium members only.
The historical data trend for Medincell's Cost of Goods Sold can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medincell (MDCLF) has a Cost of Goods Sold of $0.00 Mil as of Mar. 2026. Costs of good sold is the total amount of inventory a company sold during a given period. View historical data on Medincell and its competitors.
Is Medincell's Cost of Goods Sold too high?
Medincell's current Cost of Goods Sold is $0.00 Mil. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Cost of Goods Sold compare to VRTX and REGN?
Medincell's Cost of Goods Sold of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cost of Goods Sold for a Biotechnology company?
A good Cost of Goods Sold depends on the Biotechnology industry context. However, Cost of Goods Sold should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cost of Goods Sold mean?
A high Cost of Goods Sold can signal that a stock is expensive relative to its fundamentals. Costs of good sold is the total amount of inventory a company sold during a given period. View historical data on Medincell and its competitors. Medincell's current Cost of Goods Sold is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Cost of Goods Sold of $0.00 Mil. The stock's GF Value™ is $35.42, compared to a current price of $34.39 — trading 2.9% below its estimated fair value. The current Cost of Goods Sold is $0.00 Mil. Medincell's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cost of Goods Sold calculated?
Cost of Goods Sold is calculated from a company's financial statements. For Medincell (MDCLF), the current Cost of Goods Sold is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be undervalued.
The current stock price of $34.39 is trading 2.9% below its estimated GF Value™ of $35.42.
Key valuation signals for MDCLF:
Cost of Goods Sold: $0.00 Mil
GF Value™: $35.42 vs. price of $34.39 (2.9% below fair value)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Cost of Goods Sold is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
